Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients.
Lewis
R L
RL
Department of Renal Transplantation, Loyola University Medical Center, Maywood, Illinois 60153, USA.
Canafax
D M
DM
Pettit
K G
KG
DiCesare
J
J
Kaniecki
D J
DJ
Arnold
R J
RJ
Roberts
M S
MS
D000284:Administration, Oral; D000328:Adult; D002102:Cadaver; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D016572:Cyclosporine / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D004304:Dosage Forms; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000191:economics / Q000276:immunology* / Q000502:physiology; D007902:Length of Stay; D008390:Markov Chains; D014019:Tissue Donors; D014481:United States
D004304:Dosage Forms; D007166:Immunosuppressive Agents; D016572:Cyclosporine